BFC Planning’s Filana Therapeutics FLNA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$728 Sell
822
-2,589
-76% -$2.44K ﹤0.01% 3233
2026
Q2
$4.06K Hold
3,411
– – ﹤0.01% 2750
2026
Q1
$5.76K Hold
3,411
– – ﹤0.01% 2255
2025
Q4
$6.75K Hold
3,411
– – ﹤0.01% 2236
2025
Q3
$9.9K Hold
3,411
– – ﹤0.01% 1927
2025
Q2
$6.17K Buy
3,411
+2,589
+315% +$4.61K ﹤0.01% 1986
2025
Q1
$1.23K Hold
822
– – ﹤0.01% 2411
2024
Q4
$1.94K Hold
822
– – ﹤0.01% 2286
2024
Q3
$24.2K Buy
+822
New +$18.9K ﹤0.01% 1373

Other funds holding FLNA

BFC Planning's FLNA Position: Q3 2026 in Review

BFC Planning reduced its Filana Therapeutics (FLNA) stake by 76% in Q3 2026, selling an estimated $2.44K and leaving 822 shares worth $728. The position accounts for ﹤0.01% of the portfolio, ranked #3233.

BFC Planning first reported a position in FLNA in Q3 2024 and has held it in 9 quarters since. The position peaked at $24.2K in Q3 2024. 60 funds tracked by Wall St. Rank hold FLNA as of Q3 2026.

  • BFC Planning held 822 shares of Filana Therapeutics worth $728 as of Q3 2026.
  • BFC Planning sold 2,589 Filana Therapeutics shares in Q3 2026, an estimated $2.44K.
  • Filana Therapeutics made up ﹤0.01% of BFC Planning's portfolio in Q3 2026, its #3233 holding.
  • BFC Planning first reported a position in Filana Therapeutics in Q3 2024 and has held it in 9 quarters since.
  • BFC Planning's Filana Therapeutics position peaked at $24.2K in Q3 2024.
  • 60 funds tracked by Wall St. Rank held Filana Therapeutics as of Q3 2026.

Based on BFC Planning's 13F filing for Q3 2026, filed 13 Nov 2026.